Functional Study of Inhibitory Neurotransmission in the Human Epileptic Brain.

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNeuromed IRCCS

About this trial

Epilepsy is a neurological condition that afflicts 1% of the world population. 30% of patients become drug-resistant to classic antiepileptic treatment and only a small percentage, 5%, can undergo a neurosurgical resection of epileptic focus and recover almost completely from symptoms. To date, an imbalance between inhibitory and excitatory neurotransmission has been well accepted as the main root cause of epilepsy. A better understanding of the molecular mechanisms of this can lead to developing new therapeutic strategies. The investigators of the project want to describe the functional alteration of GABA- A receptor, the main actor of inhibitory neurotransmission in the central nervous system and characterize its subunit composition in the epileptic foci of patients with temporal lobe epilepsy. The authors, also, want to modulate, by means of selective neuroactive molecules, the function of this receptor to increase the inhibitory tone in the epileptic brain.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Patients suffering from Temporal lobe epilepsy caused by stroke, ischemia, cavernous angiomas, or meningiomas growth.

Trial population

Patients with drug-resistant TLE who undergo neurosurgery for resection of epileptic focus

Trial design

Design model

Case-only

Time perspective

Retrospective

Treatments tested in this trial

  • ex-vivo study

    Other intervention

    ex-vivo experiments in tissue slices obtained from biopsies

Treatment groups

60 Participants
are divided into 1 treatment group
Group A: Patients with drug resistant epilepsy1 intervention

Trial outcomes

Primary outcomes

1

Composition of GABA-A receptors that modulate macroscopic currents

WP1.1- Slices of tissue obtained from 12 patients Tratment :diazepam or nitrazepam and phenobarbital WP 1.2:- Slices of tissue obtained from 12 patients Treatment: BetaCCT and L655,708 or Furosemide .

Time frame
24 months
2

Modulation of synaptic transmission by GABA-A receptors PAMs and NAMs

WP2.1 Slices of tissue obtained from 12 patients Treatment: diazepam, phenobarbital, BetcCCt, and Furosemide, effect on inhibitory synaptic transmission WP2.2: Slices of tissue obtained from 12 patients Treatment: diazepam, phenobarbital, BetcCCt, and Furosemide, effect on excitatory synaptic transmission

Time frame
24
3

Modulation of inhibitory synaptic transmission by cholinergic, dopaminergic and serotonergic PAMs.

WP 3.1 Slices of tissue obtained from 12 patients Based on results obtained in Primary Outcome 1 and 2 Treatment: PNU dFBr, mCPGB, or L-dopa, effect on inhibitory neurotransmission.

Time frame
12

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.